Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX stock opened at $0.71 on Friday. The business has a 50-day moving average of $1.21 and a 200 day moving average of $3.41. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in EGRX. Perceptive Advisors LLC purchased a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at $971,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Eagle Pharmaceuticals during the third quarter valued at about $453,000. Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals during the third quarter worth about $96,000. Cubist Systematic Strategies LLC bought a new stake in shares of Eagle Pharmaceuticals in the second quarter worth about $145,000. Finally, AIGH Capital Management LLC grew its stake in shares of Eagle Pharmaceuticals by 2.1% in the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after purchasing an additional 25,000 shares during the last quarter. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.